Kadmon (NYSE:KDMN) had its target price raised by Jefferies Group to $16.00 in a research report released on Tuesday morning. The brokerage currently has a buy rating on the stock. Jefferies Group also issued estimates for Kadmon’s FY2021 earnings at ($2.83) EPS and FY2022 earnings at ($1.59) EPS.
Other research analysts have also issued reports about the company. Zacks Investment Research raised Kadmon from a hold rating to a buy rating and set a $4.25 price objective on the stock in a report on Friday, January 12th. HC Wainwright reaffirmed a buy rating and issued a $25.00 price objective on shares of Kadmon in a report on Friday, December 15th. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $10.21.
Shares of Kadmon (NYSE:KDMN) traded down $0.05 during midday trading on Tuesday, reaching $3.60. The company’s stock had a trading volume of 19,812 shares, compared to its average volume of 1,356,655. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Goldentree Asset Management LP grew its holdings in shares of Kadmon by 673.6% during the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock worth $5,834,000 after purchasing an additional 1,403,397 shares in the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Kadmon during the 3rd quarter worth $3,685,000. Vanguard Group Inc. grew its holdings in shares of Kadmon by 166.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after purchasing an additional 941,549 shares in the last quarter. Crestline Management LP acquired a new stake in shares of Kadmon during the 3rd quarter worth $2,011,000. Finally, Sabby Management LLC acquired a new stake in shares of Kadmon during the 2nd quarter worth $2,112,000. 51.91% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Raises Kadmon (KDMN) Price Target to $16.00” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/16/jefferies-group-raises-kadmon-kdmn-price-target-to-16-00.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.